LEISX
Price
$22.15
Change
-$0.08 (-0.36%)
Updated
Jul 31 closing price
Net Assets
766.51M
RMEBX
Price
$64.44
Change
+$0.03 (+0.05%)
Updated
Jul 31 closing price
Net Assets
118.05B
Interact to see
Advertisement

LEISX vs RMEBX

LEISX vs RMEBX Comparison Chart in %
View a ticker or compare two or three
VS
LEISX vs. RMEBX commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LEISX is a Buy and RMEBX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RMEBX has more cash in the bank: 118B vs. LEISX (767M). LEISX pays higher dividends than RMEBX: LEISX (1.69) vs RMEBX (0.99). LEISX was incepted earlier than RMEBX: LEISX (14 years) vs RMEBX (12 years). RMEBX (1.07) is less costly to investors than LEISX (0.90). LEISX is a more actively managed with annual turnover of: 115.00 vs. RMEBX (30.00). RMEBX has a lower initial minimum investment than LEISX: RMEBX (250) vs LEISX (1000000). RMEBX annual gain was more profitable for investors over the last year : 8.96 vs. LEISX (-4.51). RMEBX return over 5 years is better than : 36.13 vs. LEISX (-10.38).
LEISXRMEBXLEISX / RMEBX
Total Expense Ratio0.891.0783%
Annual Report Gross Expense Ratio0.901.0784%
Fund Existence14 years12 years-
Gain YTD12.1449.416129%
Front LoadN/AN/A-
Min. Initial Investment1000000250400,000%
Min. Initial Investment IRAN/AN/A-
Net Assets767M118B1%
Annual Yield % from dividends1.690.99170%
Returns for 1 year-4.518.96-50%
Returns for 3 years6.6432.6320%
Returns for 5 years-10.3836.13-29%
Returns for 10 years15.1990.6417%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IEOTX15.100.17
+1.14%
Voya Large Cap Growth Port S2
JRAAX88.86N/A
N/A
Janus Henderson Research A
VLLIX45.39-0.03
-0.07%
Value Line Larger Companies Focus Instl
BHCFX21.68-0.10
-0.46%
Baron Health Care Retail
FBDIX193.96-3.99
-2.02%
Franklin Biotechnology Discovery A